晚期非小细胞肺癌(NSCLC)化疗中应用注射用黄芪多糖对化疗所致骨髓抑制的影响

Effect of Injection of Astragalus Polysaccharide on Chemotherapy-induced Myelosuppression in Advanced Non-small Cell Lung Cancer(NSCLC) Chemotherapy

目的探讨晚期非小细胞肺癌(NSCLC)化疗中应用注射用黄芪多糖对化疗所致骨髓抑制的影响。方法选择自2014年1月—2016年12月收治的100例晚期非小细胞肺癌(NSCLC)患者作为研究对象,按照随机数字表法进行分组,分为对照组50例与研究组50例;两组均接受化疗治疗,在此基础上,研究组联合应用注射用黄芪多糖治疗,比较分析两组治疗效果、相关实验室指标以及化疗所致骨髓抑制情况。结果研究组的治疗总有效率为94.00%,更高于对照组的80.00%,组间比较差异有统计学意义(χ^2=4.332 4,P<0.05);研究组的WBC为(6.07±2.78)×10^9/L,中性粒细胞为(5.32±2.25)×10^9/L,CD3+CD4指标为(29.20±8.52)%,更高于对照组的(4.50±1.62)×10^9/L、(3.20±1.35)×10^9/L、(23.95±8.98)%,组间比较差异有统计学意义(t=2.803 0、4.641 3、2.436 4,P<0.05);研究组的CD3+CD8为(24.35±7.01)%,更低于对照组的(27.99±7.55)%,组间比较差异有统计学意义(t=2.029 6,P<0.05);研究组的血红细胞减少发生率为16.00%,与对照组的18.00%比较差异无统计学意义(χ^2=0.070 9,P>0.05);研究组的白细胞减少发生率为14.00%,血小板减少发生率为8.00%,均更低于对照组的50.00%、38.00%,组间比较差异有统计学意义(χ^2=14.889 7、12.704 7 P<0.05)。结论在临床给予晚期非小细胞肺癌(NSCLC)化疗治疗过程中,应用注射用黄芪多糖,可以有效降低或者预防化疗所致骨髓抑制,有效保护骨髓,有效提高临床治疗效果,改善疾病症状。

Objective To investigate the effect of injection of Astragalus polysaccharides on chemotherapy -induced myelosuppression in advanced non-small cell lung cancer (NSCLC) chemotherapy. Methods One hundred patients with advanced non-small cell lung cancer (NSCLC) who were admitted from January 2014 to December 2016 were enrolled in the study. The patients were divided into 50 patients in the control group and 50 patients in the study group accord-ing to the random number table method. Both groups received chemotherapy treatment. On this basis, the study group was treated with Astragalus polysaccharides for injection, and the treatment effects, related laboratory indicators and chemotherapy -induced myelosuppression were compared. Results The total effective rate of the study group was 94.00%, which was higher than that of the control group (80.00%). There was statistically significant difference between the groups (χ^2 =4.332 4, P<0.05). The WBC of the study group was (6.07±2.78)×10^9 /L, neutrophils were (5.32±2.25)× 10^9 /L, CD3+CD4 index was (29.20±8.52)%, higher than control group (4.50±1.62)×10^9 /L,(3.20±1.35)×10^9 /L,(23.95± 8.98)%, there was statistically significant difference between the groups(t=2.803 0, 4.641 3, 2.436 4, P<0.05);the study group CD3+CD8 was(24.35±7.01)%, lower than that of the control group (27.99±7.55)%, and there was statistically sig-nificant difference between the groups (t=2.029 6, P<0.05). The incidence of red blood cell reduction in the study group was 16.00%, which was not statistically significant compared with 18.00% of the control group. The difference was not statistically significant (χ^2 =0.070 9, P>0.05). The incidence of leukopenia in the study group was 14.00%, and the inci-dence of thrombocytopenia was 8.00%, which was lower than 50.00% and 38.00% in the control group and the differ-ence was statistically significant (χ^2 =14.889 7, 12.704 7, P<0.05). Conclusion In the clinical treatment of advanced non-small cell lung cancer (NSCLC) chemotherapy, the application of Astragalus polysaccharide can effectively reduce or prevent chemotherapy-induced myelosuppression, effectively protect bone marrow, effectively improve clinical treat-ment and improve disease symptoms.